Your browser doesn't support javascript.
loading
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells.
Smith, Eric L; Harrington, Kim; Staehr, Mette; Masakayan, Reed; Jones, Jon; Long, Thomas J; Ng, Khong Y; Ghoddusi, Majid; Purdon, Terence J; Wang, Xiuyan; Do, Trevor; Pham, Minh Thu; Brown, Jessica M; De Larrea, Carlos Fernandez; Olson, Eric; Peguero, Elizabeth; Wang, Pei; Liu, Hong; Xu, Yiyang; Garrett-Thomson, Sarah C; Almo, Steven C; Wendel, Hans-Guido; Riviere, Isabelle; Liu, Cheng; Sather, Blythe; Brentjens, Renier J.
Afiliação
  • Smith EL; Cellular Therapeutics Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Harrington K; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Staehr M; Juno Therapeutics, A Celgene Company, Seattle, WA 98109, USA.
  • Masakayan R; Cellular Therapeutics Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Jones J; Cellular Therapeutics Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Long TJ; Juno Therapeutics, A Celgene Company, Seattle, WA 98109, USA.
  • Ng KY; Juno Therapeutics, A Celgene Company, Seattle, WA 98109, USA.
  • Ghoddusi M; Sloan Kettering Institute, New York, NY 10065, USA.
  • Purdon TJ; Juno Therapeutics, A Celgene Company, Seattle, WA 98109, USA.
  • Wang X; Cellular Therapeutics Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Do T; Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Pham MT; Juno Therapeutics, A Celgene Company, Seattle, WA 98109, USA.
  • Brown JM; Juno Therapeutics, A Celgene Company, Seattle, WA 98109, USA.
  • De Larrea CF; Juno Therapeutics, A Celgene Company, Seattle, WA 98109, USA.
  • Olson E; Cellular Therapeutics Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Peguero E; Amyloidosis and Myeloma Unit, Department of Hematology, Hospital Clinic, August Pi i Sunyer Biomedical Research Institute, University of Barcelona, 08036 Barcelona, Spain.
  • Wang P; Juno Therapeutics, A Celgene Company, Seattle, WA 98109, USA.
  • Liu H; Sloan Kettering Institute, New York, NY 10065, USA.
  • Xu Y; Eureka Therapeutics, Emeryville, CA 94608, USA.
  • Garrett-Thomson SC; Eureka Therapeutics, Emeryville, CA 94608, USA.
  • Almo SC; Eureka Therapeutics, Emeryville, CA 94608, USA.
  • Wendel HG; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
  • Riviere I; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
  • Liu C; Sloan Kettering Institute, New York, NY 10065, USA.
  • Sather B; Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Brentjens RJ; Eureka Therapeutics, Emeryville, CA 94608, USA.
Sci Transl Med ; 11(485)2019 03 27.
Article em En | MEDLINE | ID: mdl-30918115
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Imunoterapia Adotiva / Receptores Acoplados a Proteínas G / Receptores de Antígenos Quiméricos / Mieloma Múltiplo Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Imunoterapia Adotiva / Receptores Acoplados a Proteínas G / Receptores de Antígenos Quiméricos / Mieloma Múltiplo Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article